Smith Group Asset Management LLC Raises Stock Holdings in DaVita Inc. (NYSE:DVA)

Smith Group Asset Management LLC boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 12.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 6,580 shares of the company’s stock after acquiring an additional 720 shares during the quarter. Smith Group Asset Management LLC’s holdings in DaVita were worth $1,079,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in DVA. Nisa Investment Advisors LLC boosted its position in shares of DaVita by 0.3% during the third quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock worth $6,036,000 after buying an additional 126 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of DaVita by 2.1% in the third quarter. DekaBank Deutsche Girozentrale now owns 14,013 shares of the company’s stock valued at $2,274,000 after purchasing an additional 292 shares during the period. GHP Investment Advisors Inc. increased its stake in DaVita by 0.9% during the 3rd quarter. GHP Investment Advisors Inc. now owns 45,725 shares of the company’s stock worth $7,496,000 after buying an additional 419 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in DaVita by 8.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 3,482 shares of the company’s stock valued at $571,000 after buying an additional 269 shares during the period. Finally, Forsta AP Fonden increased its position in shares of DaVita by 2.6% during the third quarter. Forsta AP Fonden now owns 35,000 shares of the company’s stock worth $5,738,000 after acquiring an additional 900 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Price Performance

Shares of NYSE DVA opened at $157.05 on Tuesday. The stock’s 50-day simple moving average is $158.18 and its 200-day simple moving average is $145.85. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The firm has a market capitalization of $13.18 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. DaVita Inc. has a fifty-two week low of $75.47 and a fifty-two week high of $168.50.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. During the same quarter last year, the company earned $2.08 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities research analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 over the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DVA shares. TD Cowen boosted their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. UBS Group upped their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Finally, Truist Financial increased their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average price target of $159.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.